Inclacumab, which Pfizer obtained in its 2022 acquisition of Global Blood Therapeutics, failed to significantly lower pain ...

Pfizer set about evaluating inclacumab in pair of phase 3 studies, dubbed Thrive. The Big Pharma terminated one of those ...

Global Blood Therapeutics novel sickle cell disease drug, Oxbryta, continues to outperform revenue expectations early in its launch despite the "pandemic era". It is evident in both the data and ...

Global Blood Therapeutics provided investors with a preliminary update from its phase 3 HOPE study. This 154-patient trial is testing its drug Voxelotor as a treatment for kids with sickle cell ...

What happenedShares of hematology biotech Global Blood Therapeutics (NASDAQ: GBT) are up 16.5% as of 10:30 a.m. EDT after the company posted upbeat second-quarter 2021 earnings. Sales of its ...

Trading at a P/B of 5.73x, Global Blood Therapeutics seems to be a reasonably valued stock. Despite the risk profile of the company, I feel that this can emerge as a major SCD player in future years.

What: Global Blood Therapeutics (GBT) is down 19% at 12:30 p.m. EST after releasing data for its sickle cell drug GBT440 at the American Society of Hematology (ASH) meeting over the weekend.

Global Blood, based in South San Francisco, Calif., had expected to price its offering at $16 to $18 per share. Its stock is listed on the Nasdaq Global Market under the symbol “GBT.” Policies ...

Global Blood Therapeutics said it is selling 5.1 million shares of common stock to the public for $24.50 per share. That should net the company $125 million after deducting fees.

San Francisco and Boston – June 14, 2012 – Third Rock Ventures, LLC today announced the formation of Global Blood Therapeutics, Inc. and its $40.7 million Series A financing of the company.